Allergy London is very pleased to be able to offer a new treatment option, Remibrutinib (Rhapsido), for appropriate adult patients with chronic spontaneous urticaria whose symptoms are not adequately controlled by antihistamines.
Remibrutinib is an oral medication taken as a 25mg film-coated tablet.
Chronic spontaneous urticaria is a long-term condition that causes recurring hives (raised, itchy skin), itching and swelling. In people with the condition, the immune system can become overactive, leading to inflammation and the development of these symptoms.
Remibrutinib works by blocking a protein in the immune system called Bruton’s tyrosine kinase (BTK). This protein is involved in the processes that cause inflammation and by blocking BTK, this helps reduce the immune activity involved in Chronic spontaneous urticaria, which can make itching and hives less frequent and less severe.
The approval of Remibrutinib follows an assessment of evidence from two main clinical studies involving 925 adults with chronic spontaneous urticaria whose symptoms were not adequately controlled with H1 antihistamines. In these studies, people treated with Remibrutinib experienced significantly greater reductions in itching and hives compared with those who received placebo (a treatment with no active medicine).
Professor Adam Fox OBE, Co-founder of Allergy London, shared:
“Remibrutinib represents an important new treatment option for adults living with chronic spontaneous urticaria whose symptoms remain inadequately controlled by antihistamines. Whereas up until now our second line choice was injectable Omalizumab, we now have an oral option that will suit some patients better.
“We are very pleased to be able to offer this treatment to appropriate patients, affirming our commitment to ensure access to the most up to date treatments as soon as they are available.”
